173 - Challenging Cases in Immunocompromised Host

Tuesday, October 21, 2025

3:15 PM - 4:30 PM US ET

Location: Sidney J. Marcus Auditorium

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Interactive Moderator(s)

Murat Akova, Prof. (he/him/his)

Professor
Hacettepe University
Ankara, Ankara, Turkey
Joanna Schaenman, MD, PhD, FAST (she/her/hers)

Professor, Department of Medicine, Division of Infectious Diseases
University of California Los Angeles, David Geffen School of Medicine
Los Angeles, CA, United States

Slides

Panelist(s)

Stephanie Pouch, MD, MS, FAST, FIDSA (she/her/hers)

Associate Professor
Division of Infectious Diseases, Department of Medicine
Emory University School of Medicine
Atlanta, GA, United States
Ricardo La Hoz, MD

Associate Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX, United States
BG

Blanca Gonzalez, MD (she/her/hers)

Associate Professor of Pediatrics
Pediatrics/Center for Pediatric Infectious Diseases
Cleveland Clinic Children's
Cleveland, OH, United States
MS

Michael Satlin, MD, MS

Associate Professor
Medicine
Weill Cornell Medicine
New York, NY, United States

Disclosure(s):

Murat Akova, Prof.: No financial relationships to disclose.

Joanna M. Schaenman, MD, PhD, FAST: Merck and Company, Inc.: Grant/Research Support

Stephanie M. Pouch, MD, MS, FAST, FIDSA: Wiley (Blackwell): Associate Editor, TID Journal

Ricardo M. La Hoz, MD: Amivas: DSMB for Phase II Clinical Trial

Blanca E. Gonzalez, MD: No financial relationships to disclose.

Michael J. Satlin, MD, MS: AbbVie: DSMB participant; bioMerieux: Grant/Research Support; Merck: Grant/Research Support; SNIPRBiome: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:

identify diagnostic approaches for infections in patients with severe immunosuppression including transplant patients;
develop a differential diagnosis of causes of fever in immunosuppressed patients;
identify treatment modalities of infections in immunocompromised patients;
identify prognostic factors for morbidity and mortality in patients with severe immunosuppression.